Evidence map›Paper›PMID 34168646›Full record

ArticleFrontiers in immunology2021

Serum Antibodies Against the Oncogenic Merkel Cell Polyomavirus Detected by an Innovative Immunological Assay With Mimotopes in Healthy Subjects.

Chiara Mazziotta, Carmen Lanzillotti, Elena Torreggiani, Lucia Oton-Gonzalez, Maria Rosa Iaquinta, Elisa Mazzoni, Pauline Gaboriaud, Antoine Touzé, Ettore Silvagni, Marcello Govoni and 3 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Chiara MazziottaDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Carmen LanzillottiDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Elena TorreggianiDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Lucia Oton-GonzalezDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Maria Rosa IaquintaDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Elisa MazzoniDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Pauline GaboriaudISP "Biologie des infections à polyomavirus" Team, UMR INRA 1282, University of Tours, Tours, France.
Antoine TouzéISP "Biologie des infections à polyomavirus" Team, UMR INRA 1282, University of Tours, Tours, France.
Ettore SilvagniDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Marcello GovoniDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Fernanda MartiniDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Mauro TognonDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
John Charles RotondoDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
University of Ferrara · ITInfectiologie Animale et Santé Publique · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell polyomavirus (MCPyV), a small DNA tumor virus, has been detected in Merkel cell carcinoma (MCC) and in normal tissues. Since MCPyV infection occurs in both MCC-affected patients and healthy subjects (HS), innovative immunoassays for detecting antibodies (abs) against MCPyV are required. Herein, sera from HS were analyzed with a novel indirect ELISA using two synthetic peptides mimicking MCPyV capsid protein epitopes of VP1 and VP2. Synthetic peptides were designed to recognize IgGs against MCPyV VP mimotopes using a computer-assisted approach. The assay was set up evaluating its performance in detecting IgGs anti-MCPyV on MCPyV-positive (n=65) and -negative (n=67) control sera. Then, the ELISA was extended to sera (n=548) from HS aged 18-65 yrs old. Age-specific MCPyV-seroprevalence was investigated. Performance evaluation indicated that the assay showed 80% sensitivity, 91% specificity and 83.9% accuracy, with positive and negative predictive values of 94.3% and 71%, respectively. The ratio expected/obtained data agreement was 86%, with a Cohen's kappa of 0.72. Receiver-operating characteristic (ROC) curves analysis indicated that the areas under the curves (AUCs) for the two peptides were 0.82 and 0.74, respectively. Intra-/inter-run variations were below 9%. The overall prevalence of serum IgGs anti-MCPyV in HS was 62.9% (345/548). Age-specific MCPyV-seroprevalence was 63.1% (82/130), 56.7% (68/120), 64.5% (91/141), and 66.2% (104/157) in HS aged 18-30, 31-40, 41-50 and 51-65 yrs old, respectively (p>0.05). Performance evaluation suggests that our indirect ELISA is reliable in detecting IgGs anti-MCPyV. Our immunological data indicate that MCPyV infection occurs asymptomatically, at a relatively high prevalence, in humans.

Indexed as

AdultAntibodies, ViralAsymptomatic InfectionsCapsid ProteinsComputer SimulationData AccuracyDiagnosis, Computer-AssistedEnzyme AssaysEnzyme-Linked Immunosorbent AssayEpitopesFemaleHealthy VolunteersHumansImmunoglobulin GMaleMerkel cell polyomavirusAntibodies, ViralCapsid ProteinsEpitopesImmunoglobulin GantibodiesIgGsindirect ELISAMCPyVMerkel cell carcinomaMerkel cell polyomaviruspolyomavirusserology

Identifiers

PMID34168646
PMCPMC8217635
OpenAlexW3171711666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.